Sarcosine
|
Basic information |
| Metabolite name | Sarcosine |
 | HMDB0000271 |
 |
C00213 |
 |
1088 |
| Synonyms | NA |
| No. of studies | 22 |
|
Basic information |
| Metabolite name | Sarcosine |
| HMDB0000271 |
|
C00213 |
|
1088 |
| Synonyms | NA |
| No. of studies | 22 |
|
Relationship between Sarcosine and depression (count: 22) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M065 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M086 | Type5 | paroxetine-treated responder group vs. non-responder group | Hippocampus | DBA/2J mouse | Up |
| Study M094 | Type1 | PSD group vs. stroke and control group | Urine | Human | Down |
| Study M108 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1102 | Type1 | nitenpyram group vs. control group, female offspring | Faece | ICR mouse | Up |
| Study M112 | Type5 | paroxetine-treated responder group vs. non-responder group | Hippocampus | DBA/2J mouse | Up |
| Study M474 | Type1 | olfactory bulbectomy group vs. control group | Plasma | C57BL/6J mouse | Down |
| Study M547 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M565 | Type1 | CUMS group vs. control group | Intestine | C57BL/6 mouse | Up |
| Study M565 | Type2 | CUMS + minocycline group vs. CUMS group | Intestine | C57BL/6 mouse | Down |
| Study M577 | Type1 | male depression group vs. male control group, aged 40-49 | Urine | Human | Unknown |
| Study M602 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M692 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M712 | Type1 | depression group vs. control group | Faece | Cynomolgus monkey | Up |
| Study M741 | Type2 | MDD group, post vs. before SSRI treatment | Plasma | Human | Down |
| Study M741 | Type4 | remitter group vs. non-remitter group, posttreatment | Plasma | Human | Up |
| Study M741 | Type4 | remitter group vs. non-remitter group, baseline | Plasma | Human | Up |
| Study M840 | Type1 | casein-rich milk group vs. control group | Urine | Wistar rat | Down |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Up |
| Study M909 | Type3 | hydroxynorketamine group vs. control group | Plasma | CD-1 mouse | Down |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M950 | Type2 | probiotic group vs. placebo group | Faece | Human | Up |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |